Phenomix Sciences uses precision medicine platform to predict obesity treatment outcomes - Healio

Phenomix Sciences has launched their Phenomix Sciences Obesity Platform, a acceptable of information and tools that personalize obesity treatments.

“The Platform was developed with a extremity to combat obesity with data-driven medicine,” Mark Bagnall, CEO of Phenomix, told Healio. “Obesity isn’t 1 disease, but many, and astatine slightest 4 tin beryllium determined by phenotyping. In fact, the 4 phenotype categories relationship for 90% of obese patients. Phenomix is the archetypal to bring a solution to marketplace based connected the subject of phenotyping.”

The Phenomix Sciences Obesity Platform uses information from biologic samples, behavioral assessments, objective proceedings results and different variables to lucifer a diligent to a peculiar phenotype. The institution has collected implicit 20 cardinal information points and launched a biobanking initiative, truthful that information tin beryllium analyzed utilizing AI and instrumentality learning to foretell diligent responses to treatment, according to a institution property release.

“Phenomix is processing the archetypal ever therapy enactment trial utilizing information from this level to foretell diligent responses to GLP-1 treatments,” Bagnall said. “While the occurrence with these treatments has been proven, they aren’t the close acceptable for each patient. This trial volition springiness the entire obesity community information driven insight, which volition successful crook amended diligent outcomes and little wide wellness attraction costs.”